rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment

Thomas P. Monath a,1, Patricia E. Fast b, Kayvon Modjarrad c, David K. Clarke d, Brian K. Martin a,2, Joan Fusco a,1, Richard Nichols a,1, D. Gray Heppner b,1, Jakub K. Simon e, Sheri Dubey e, Sean P. Troth e, Jayanthi Wolfe e, Vidisha Singh f, Beth-Ann Colle e, James S. Robertson e,g, For the Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) 3

a NewLink Genetics Corp, Ames, IA, United States
b International AIDS Vaccine Initiative, New York, NY 10004, United States
c Walter Reed Army Institute of Research, Silver Spring, MD 20910, United States
d Profectus Inc., Pearl River, NY 10965, United States
e Merck & Co., Inc., Kenilworth, NJ 07033, United States
f Immunology and Molecular Pathogenesis, Emory University, Atlanta, GA 30322, United States
g Independent Expert, United Kingdom

Article info

Article history:
Received 30 November 2018
Accepted 7 December 2018
Available online 29 January 2019

Keywords:
Vaccines
Ebola vaccine
Vesicular stomatitis virus vector
Viral vector
Brighton collaboration
Risk/benefit assessment
Vaccine safety

ABSTRACT

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. A recent publication by the V3SWG described live, attenuated, recombinant vesicular stomatitis virus (rVSV) as a chimeric virus vaccine for HIV-1 (Clarke et al., 2016). The rVSV vector system is being explored as a platform for development of multiple vaccines. This paper reviews the molecular and biological features of the rVSV vector system, followed by a template with details on the safety and characteristics of a rVSV vaccine against Zaire ebolavirus (ZEBOV). The rVSV-ZEBOV vaccine is a live, replication competent vector in which the VSV glycoprotein (G) gene is replaced with the glycoprotein (GP) gene of ZEBOV. Multiple copies of GP are expressed and assembled into the viral envelope responsible for inducing protective immunity. The vaccine (designated V920) was originally constructed by the National Microbiology Laboratory, Public Health Agency of Canada, further developed by NewLink Genetics Corp. and Merck & Co., and is now in final stages of registration by Merck. The vaccine is attenuated by deletion of the principal virulence factor of VSV (the G protein), which also removes the primary target for anti-vector immunity. The V920 vaccine caused no toxicities after intramuscular (IM) or intracranial injection of nonhuman primates and no reproductive or developmental toxicity in a rat model. In multiple studies, cynomolgus macaques immunized IM with a wide range of virus doses rapidly developed ZEBOV-specific antibodies measured in IgG ELISA and neutralization assays and were fully protected against lethal challenge with ZEBOV virus. Over 20,000 people have received the vaccine in clinical trials; the vaccine has proven to be safe and well tolerated. During the first few days after vaccination, many vaccinees experience a mild acute-phase reaction with fever, headache, myalgia, and arthralgia of short duration; this period is associated with a low-level viremia, activation of anti-viral genes, and increased levels of chemokines and cytokines. Oligoarthritis and rash appearing in the second week occur at a low incidence, and are typically mild-moderate in severity and self-limited. V920 vaccine was used in a Phase III efficacy trial during the West African Ebola epidemic in 2015, showing 100% protection against Ebola Virus Disease, and it has subsequently been deployed for emergency control of Ebola outbreaks in central Africa. The template

https://doi.org/10.1016/j.jvacx.2019.100009
2590-1362/© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Recombinant viral vectors expressing heterologous antigens (and antibodies) represent promising platforms for developing novel vaccines and therapies against human and animal infectious diseases and cancers. Development of new viral vectors, remodeling of vector backbones to improve their biological activity, and incorporation of new foreign proteins in existing vector platform result in unique viral products requiring assessments of safety, innate and adaptive immune response, manufacturability and the regulatory pathway. It is important to understand how chimeric viral vectors differ from the wild-type progenitors, based on modifications within the vector backbone and the effect of adding a heterologous gene, which may influence pathogenesis. This is particularly true for replicating, attenuated vaccines (as distinguished from replication defective vectors (e.g. adenoviruses, alphavirus replicons, and herpes simplex viruses), or live vectors that are attenuated due to host range restriction (e.g. Modified Vaccinia Ankara, Sendai, and Newcastle disease viruses). In general, replicating vaccines have proven most effective in generating rapid and durable protection against viral infections [1]. A number of rationally developed, recombinant, replicating, attenuated viral vector vaccines are in clinical development, and a few are nearing licensure or have reached commercialization. Among the prominent platforms for constructing such vaccines are vaccinia virus, (veterinary applications) [2]; measles virus [3]; adenovirus type 4 [4]; alphaviruses, such as Sindbis and Venezuelan equine encephalitis virus [5]; flaviviruses, including dengue virus and yellow fever virus 17D [6]; cytomegalovirus [7]; and vesicular stomatitis virus [8], the subject of this paper.

The Brighton Collaboration (www.brightoncollaboration.org) was formed in 2000 as an international voluntary collaboration to enhance the science of vaccine safety research [9]. In recognition of these needs in this domain, the Brighton Collaboration created the Viral Vector Vaccines Safety Working Group (V3SWG) in October 2008. Analogous to the value embodied in standardized case definitions for Adverse Events Following Immunization (AEFI), the V3SWG believes a standardized template describing the key characteristics of a novel vaccine vector, when completed and maintained with the latest research, will facilitate the scientific discourse among key stakeholders by increasing the transparency and comparability of information. The International AIDS Vaccine Initiative (IAVI) had already developed an internal tool to assess the risk/benefit of different viral vectors under its sponsorship. The IAVI graciously shared this tool with the V3SWG for adaptation and broader use as a standardized template for collection of key information for risk/benefit assessment on any viral vector vaccines. This tool was aimed at identifying potential major hurdles or gaps that would need to be addressed during the development of vectored vaccines. The template collects information on the characteristics of the wild type virus from which the vector was derived as well as known effects of the proposed vaccine vector in animals and humans, manufacturing features, toxicology and potency, nonclinical studies, and human use, with an overall adverse effect and risk assessment.

Following the process described above and on the Brighton Collaboration Website (http://cms.brightoncollaboration.org:8080/public/what-we-do/setting-standards/case-definitions/process.html), the Brighton Collaboration V3SWG was formed in October 2008 and includes ~15 members with clinical, academic, public health, regulatory and industry backgrounds with appropriate expertise and interest. The composition of the working and reference group, as well as results of the web-based survey completed by the reference group with subsequent discussions in the working group, can be viewed at http://www.brightoncollaboration.org/internet/en/index/workinggroups.html. The group meets via emails and monthly conference calls coordinated by a secretariat [9].

The V3SWG anticipates that eventually all developers/researchers of viral vector vaccines (especially those in clinical development) will complete the template and submit it to the V3SWG and Brighton Collaboration for peer review and eventual publication in Vaccine. Following this, to promote transparency, the template will be posted and maintained on the Brighton Collaboration website for use/reference by various stakeholders. Furthermore, recognizing the rapid pace of new scientific developments in this domain (relative to AEFI case definitions), we hope to maintain these completed templates “wiki” style with the help of Brighton Collaboration and each vectored vaccine community of experts [10].

1.1. Vesicular stomatitis virus (VSV) as a platform for recombinant, replicating vaccines

This paper is preceded by a recent V3SWG and Brighton Collaboration publication by Clarke et al. [8] describing the history and rationale for development of VSV as a replicating vector platform; the natural history of parental VSV viruses; the construction of recombinant vaccines pseudo-typed with heterologous proteins that stimulate humoral and cellular immunity; attenuation strategies; the application of animal models to test safety and efficacy; manufacturing; and the status of clinical development. The underlying principles explained by Clarke et al. [8] are critical background to the present paper. A number of general points are re-emphasized below, and additional background is provided to facilitate an understanding of the recombinant rVSV platform as applied to the development of vaccines against viral hemorrhagic fevers. These comments are followed by the template which provides specific features of the most advanced rVSV vector in development, a vaccine against Ebola virus disease in which the VSV glycoprotein (G) is entirely deleted and replaced with the corresponding glycoprotein (GP) of the Zaire Ebolavirus (rVSVAG-ZEBOV-GP). This vaccine, currently designated V920, is being developed by Merck & Co., Kenilworth, NJ, USA and is in the registration process.

1.1.1. Aspects of the rVSV technology of special interest for vaccine development

a. VSV (a negative sense, single-strand RNA virus belonging to the family Rhabdoviridae, genus Vesiculovirus) is being widely explored for vaccine development against infectious diseases and cancer, and as an oncolytic virus.

b. VSV causes self-limited disease in horses, pigs, and cattle, and may be either asymptomatic or cause a mild flu-like syndrome in humans and is thus a naturally attenuated vector backbone for development of human vaccines and therapies.
c. Other advantages of VSV as a vector include (i) low prevalence of immunity to the vector in most populations targeted for immunization; (ii) the viral RNA does not integrate into the host, posing little risk of oncogenesis or mutagenesis; (iii) large foreign transgenes can be packaged and expressed; (iv) the virus may be pseudo-typed with heterologous viral glycoproteins presented in the envelope in their natural conformation.

d. There are two major VSV serotypes (VSV-Indiana and VSV-New Jersey). VSV-Indiana (VSV-I) is the basis for current vaccine candidates. Other related vesiculoviruses, such as Isfahan virus [11] and Maraba virus [12], and more distinctly related rhabdoviruses, such as rabies virus are also being explored as viral vectors [13].
e. The VSV genome consists of ~11,000 nucleotides encoding five major proteins. The VSV glycoprotein (G) located in the viral envelope is responsible for attachment to cells, fusion with endosomal membranes at low pH and release of viral genomic RNA into the cytoplasm. The G protein also elicits protective immunity against VSV.
f. Using reverse genetic systems, VSV vectors have been constructed expressing genes from divergent species, including many viruses (e.g. Ebola virus, Marburg virus, Lassa fever virus, HIV, influenza virus, EV71, HPV and others, see template), bacteria [14], and tumor antigens [15]. In some constructs, a portion of the VSV G protein is retained to facilitate expression or enable fusion and internalization of the recombinant virus [8]. VSV vectors completely lacking the VSV G gene (VSVΔG) must reconstitute the attachment, fusion and budding (release) functions with one or more proteins encoded by the heterologous envelope gene. In the case of rVSVΔG-influenza, for example, VSV G was replaced with influenza hemagglutinin (HA), neuraminidase (NA) or both; only virus expressing both HA and NA in the same vector produced replication-competent pseudo-type virus [16], since both proteins play a role in attachment and because NA is needed for virus release from host cells. Similarly, in the case of a henipavirus (Nipah), a pseudo-type expressing the Nipah glycoprotein (G) responsible for cell attachment did not produce replicating virus unless a fusion protein [F protein of Nipah or the glycoprotein (GP) of Ebola Zaire] was coexpressed [17].
g. Replicating rVSVΔG pseudotypes with glycoprotein (GP) derived from many different filoviruses [Ebola zaire, Ebola sudan, Ebola reston, Marburg, Bundibugyo, Tai Forest, and Lloviu have been constructed [18–20], with the GP providing virus attachment and class I fusion functions. The most advanced vaccine candidate described in this template is rVSVΔG-ZEBOV-GP expressing Zaire Ebola virus (ZEBOV) GP in place of the VSV-I G protein.
h. The reverse genetics system producing rVSVΔG-ZEBOV-GP involves co-transfection of cells with plasmids containing the entire VSV genome with G deleted and replaced with ZEBOV GP, together with helper plasmids expressing the VSV N, P, and L genes [28]. Transcription of the plasmids is controlled by bacteriophage T7 polymerase supplied by baby hamster kidney cells expressing T7 (as done for rVSVΔG-ZEBOV-GP) or exogenously by a recombinant vaccinia expressing T7 polymerase.
i. The rVSVΔG-ZEBOV-GP is constructed with full-length GP anchored in the viral envelope, whereas native ZEBOV expresses an abundant soluble form of GP without the transmembrane domain (soluble GP, sGP), which may act as a decoy for antibody contributing to evasion of neutralizing antibody during filovirus infection [21]. As, rVSVΔG-ZEBOV-GP generates no sGP it is more efficiently neutralized by antibody than wild-type ZEBOV [22].
j. The full length heterologous GP is incorporated into the rVSV particle, which retains typical bullet shaped morphology, the viral envelope being decorated with ZEBOV GP spikes instead of VSV G protein spikes. The GP spike is composed of disulfide linked subunits, GP1 and GP2. Three GP1 sub-units form a 3-bladed propeller-like trimer consisting of the receptor binding domains, glycosylated mucin-like domains and glycan caps. The glycans are hypothesized to shield epitopes from neutralizing antibody [23,24]. However this is uncertain, since neutralization can occur prior to cleavage of the mucin-like domain in the endosome. Moreover, a mutated rVSVΔG-ZEBOV-GP lacking GP1 glycans was not more efficient in eliciting neutralizing antibodies in mice [26].
k. In standard EM studies, insertion of Ebola GP into rVSV particles did not alter typical bullet-shaped vesiculovirus morphology. However, while the structure of the ZEBOV GP has been partially resolved by cryo-EM at high resolution [23] that of GP in pseudo-typed VSV has not been elucidated.
l. The cell targets for infection, determined by virus ligand-cell receptor interactions, may differ for virus pseudo-typed with ZEBOV GP compared to natural VSV, although there may be overlapping tropisms. Certain cell lines susceptible to VSV but not ZEBOV, such as Jurkat cells and insect cells, do not permit rVSVΔG-ZEBOV-GP replication [18,26]. The primary in vivo ZEBOV targeted cells are thought to be endothelial cells, monocytes, macrophages, and myeloid dendritic cells [27]. Although this is also presumed to hold true for the pseudo-typed rVSV, there is no systematic study of the cell types productively infected by rVSVΔG-ZEBOV-GP in vivo. Consistent with ZEBOV GP-specific tropism, a limited number of observations suggest that endothelial cells are a target for rVSVΔG-ZEBOV-GP [28] and a biodistribution study in macaques showed that the vaccine virus targeted lymphoreticular tissues [Merck & Co., Inc., Kenilworth, NJ, USA, NewLink Genetics Corp, unpublished data, 2017]. Interestingly, a study in swine (unpublished, described in the template) showed that rVSVΔG-ZEBOV-GP induced self-limited clinical disease, histopathology and cell tropism, similar to that induced by wild-type VSV. Although pigs are also susceptible to ZEBOV by the respiratory route [29], pathogenesis is distinct from that caused by VSV. Thus, in swine, the pathogenesis of the host-virus pairing appears to match that of the vector backbone rather than the donor of the heterologous envelope. Possibly, the retention of the intact VSV M gene, a virulence factor of VSV [30], in the recombinant rVSVΔG-ZEBOV-GP vector plays a role in pathogenesis for swine. These observations provide fertile ground for future research in mechanisms of viral pathogenesis.
m. Both wild type ZEBOV and rVSV pseudo-typed with ZEBOV GP appear to enter the cell by macropinocytosis in a GP protein-dependent manner [31]. The cell receptors initiating this process remain poorly defined and entry does not appear to involve clathrin (in contrast, VSV G protein binds low-density lipoprotein receptors and enters via receptor-mediated endocytosis by a clathrin-dependent pathway [32]). C-type lectins (e.g. DC-SIGN) are putative cell surface receptors for ZEBOV GP [33]. However, a critical virus-cell receptor interaction is intracellular, an important consideration for immune recognition. Once in the endosome, proteolytic processing is initiated by cathepsin proteases, after
which GP1 binds to receptors on endosomal membranes, predominantly the Niemann-Pick C1 protein [34]. Cleavage of the mucin-like domain and the glycan cap on G1 are required for receptor binding to occur [23]. At low pH, conformational rearrangement of GP2 exposes a hydrophobic fusion loop which is inserted into the endosome membrane followed by internalization of the viral RNA. Neutralization of Ebola virus by antibody involves multiple different mechanisms, including blocking cathepsin-mediated proteolytic cleavage of GP1, blocking binding of GP1 to Niemann Pick C1 receptors, and inhibition of GP2 mediated fusion [35,36].

n. Since the VSV G gene is deleted in rSVSAG-ZEBOV-GP, antivector immunity is minimized as a factor for primary immunization or sequential use of vectors expressing different heterologous genes.

o. Complete deletion of VSV G protein and replacement by the heterologous transgene, as in rSVSAG-ZEBOV-GP, results in a highly attenuated phenotype. Removal of VSV G, the principal virulence factor, is critical to this attenuation, since constructs retaining G or a portion thereof show varying degrees of residual neurovirulence when injected directly into the brain of young mice [8].

p. Attenuation of the rSVSAG-ZEBOV-GP vaccine candidate has been extensively studied. Neurovirulence is a feature of parental VSV infection following intracranial injection of most animal species (see template, Table 2), whereas the rSVSAG-ZEBOV-GP virus is pathogenic only for infant (not adult) mice and caused minimal histopathology without clinical signs after intracranial inoculation in non-human primates [37]. No clinical, biochemical or pathoanatomical effects were observed in mice, rats, and nonhuman primates in formal toxicology studies where the vaccine was administered IM at the full human dose (see template). The rSVSAG-ZEBOV-GP vaccine (V920) has now been administered to over 20,000 persons in Phase 1–3 and expanded access clinical trials and has been shown to have a favorable safety profile and to be generally well tolerated.

q. VSV pseudo-types can propagate to high titers in mammalian cells, although some degree of attenuation is observed compared to wild-type VSV [18]. As VSV is an interferon-sensitive virus, interferon deficient cells, such as Vero cells, are particularly productive. Vero cells are widely used for manufacturing other vaccines, including multiple licensed, live attenuated vaccines (e.g. poliovirus, smallpox virus, rotavirus, dengue virus). The rSVSAG-ZEBOV-GP virus grows to ~8.0 log10 plaque-forming units/mL (PFU/mL) in Vero cells without serum or animal derived components. The virus can then be clarified by filtration and purified and concentrated by a straightforward process involving enzyme digestion and ultrafiltration/diafiltration without chromatography and with minimal product loss. This manufacturing process has been up-scaled to produce large quantities of vaccine and is undergoing validation at a dedicated facility.

r. Many live, replicating vaccines are susceptible to thermal instability and require lyophilization for long term storage. Because of the short development time for rSVSAG-ZEBOV-GP during the West African Ebola emergency in 2014–2015, the vaccine was produced and stored in unit dose containers as a frozen liquid formulation, stored at ≤−60 °C. Interestingly, the vaccine was found to be stable when thawed and held at 2–8 °C for at least 2 weeks, a feature that facilitates distribution for use in control of outbreaks.

s. The rSVSAG-ZEBOV-GP vaccine has been extensively tested in nonhuman primates with respect to immunogenicity and protective efficacy (see template, Table 2). The published literature has been supplemented by multiple additional studies, largely aimed at determining the immune correlate(s) of protection which may then be bridged to human immune responses elicited by the rSVSAG-ZEBOV-GP vaccine. These efforts are ongoing. In one study, IgM subclass antibodies were suggested to play a dominant role in rSVSAG-ZEBOV immunity compared to IgG [38] but this observation has not been further investigated.

t. Inoculation of rSVSAG-ZEBOV-GP is followed by rapid appearance of viremia and activation of innate immune responses, including NK cells, which are believed to be at least partially responsible for protection against challenge given 3–7 days after vaccination [43–48] or shortly before vaccination (i.e. post exposure vaccination [113]). GP-specific IgG antibodies appear between 7 and 14 days after vaccination and tend to peak at 28 days. A signature of innate immune markers appearing during the first few days after vaccination was found to correlate with antibody levels appearing later. Predominant among the independent markers were IP-10 and CXCR6 expression on NK cells on day 1 as independent correlates. These observations are consistent with other live viral vaccines, such as yellow fever vaccine, showing predictive innate signatures that shape the adaptive response [39].

u. The role of neutralizing antibodies in protection elicited by rSVSAG-ZEBOV-GP vaccine remains uncertain. The vaccine elicits robust neutralizing antibody responses following vaccination as measured by plaque reduction with the homologous (vaccine) virus, or in a ZEBOV pseudo-virion assay but neutralization titers against wild-type virus appear to be low [47]. The repertoire of antibodies elicited by the vaccine is not yet known, but it is clear that neutralizing monoclonal antibodies are highly protective; passive immunization with certain monoclonal antibodies can abrogate infection and prevent illness/death in the NHP model even when given up to 5 days after challenge [40]. In addition to neutralization, non-neutralizing antibodies with functional activities, including ADCC [40] and phagocytosis are probable secondary mediators; moreover, cooperative effects of non-neutralizing antibodies may enhance the potency of neutralizing antibodies [41].

v. There have been few studies of T cell responses in NHPs or humans vaccinated with rSVSAG-ZEBOV-GP. However, the vaccine does not appear to elicit robust T cell responses in NHPs [42]. Moreover, T cell depletion studies in vaccinated NHPs indicated that CD8+ T cells did not play a role in protection [42]. In humans, broad T cell activation was observed by Day 7 after vaccination, but ZEBOV specific cytotoxic CD8+ T cell responses were seen only at the higher vaccine dose (2 × 10^7 pfu) [43], consistent with antibodies being the predominant mediator of protection.

w. A substantial experience has now accumulated on the safety, immunogenicity and protective efficacy of rSVSAG-ZEBOV-GP in humans (Table 1). It is remarkable that this effort was carried out by a coalition of multiple international partners over a short period of time and during an international public health emergency in West Africa [44]. The logistical problems and solutions encountered in one of the large trials are chronicled in a recent series of publications [45].
| Study ID          | Phase | Country | Study title                                                                 | Study design                                      | Dosing regimen (V920, IM)                           | Study population                                                                 | Status of trial subject exposure |
|-------------------|-------|---------|------------------------------------------------------------------------------|---------------------------------------------------|--------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------|
| Protocol V920-001-06 (NLG 0307; WRAIR 2163) | 1     | USA     | A Phase I Randomized, Single-Center, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (V920) Ebola Virus Vaccine Candidate in Healthy Adult Subjects | Randomized, double-blind, placebo-controlled, dose-escalation | $3 \times 10^{5} \text{pfu/mL (n = 10)}, 2 \times 10^{7} \text{pfu/mL (n = 10)}, 1 \times 10^{9} \text{pfu/mL (n = 10)}$, placebo (n = 9) | Healthy eligible subjects between the ages of 18 and 60 years                     | Completed                         |
| Protocol V920-002-04 (NLG 0207; NIH 15-1-0001) | 1     | USA     | A Phase I Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults | Randomized, double-blind, placebo controlled, dose-escalation study | $3 \times 10^{5} \text{pfu/mL (n = 10)}, 2 \times 10^{7} \text{pfu/mL (n = 10)}, 1 \times 10^{9} \text{pfu/mL (n = 10)}$, placebo (n = 9) | Healthy eligible subjects between the ages of 18 and 65 years                      | Completed                         |
| Protocol V920-003-01 (#CI1401, Halifax, Canada) | 1     | Canada  | A Phase I Randomized, Single-Center, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (V920) Ebola Virus Vaccine Candidate in Healthy Adult Subjects | Randomized, single-center, double-blind, placebo-controlled, dose-ranging | $3 \times 10^{5} \text{pfu/mL (n = 10)}, 3 \times 10^{7} \text{pfu/mL (n = 10)}$, placebo (n = 10) | Healthy eligible subjects between the ages of 18 and 65 years                      | Completed                         |
| Protocol V920-004-03 (NLG 0507) | 1b    | USA     | A Phase I Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (V920) Ebola Virus Vaccine Candidate in Healthy Adult Subjects | Randomized, multi-center, double-blind, placebo controlled, dose-ranging | $3 \times 10^{5} \text{pfu/mL (n = 64)}, 3 \times 10^{7} \text{pfu/mL (n = 64)}$, placebo (n = 64) | Healthy eligible subjects between the ages of 18 and 60 years                      | Completed                         |
| Protocol V920-005-08 (Geneva) | 1     | Switzerland | A Phase 1/2 dose-finding randomized, single-center, double-blind, placebo-controlled safety and immunogenicity trial of the vesicular stomatitis virus-vectored Zaire Ebola candidate vaccine BPSC1001 (V920) in healthy adults | Randomized, single-center, double-blind, placebo-controlled, dose-escalation study | $3 \times 10^{5} \text{pfu/mL (n = 51)}, 1 \times 10^{7} \text{pfu/mL (n = 35)}$, placebo (n = 13) | Healthy eligible subjects between the ages of 18 and 65 years                      | Completed                         |
| Protocol V920-006-05 (Hamburg) | 1     | Germany | An open label, single center, dose escalation Phase 1 trial to assess the safety, tolerability and immunogenicity of a single ascending dose of the Ebola Virus vaccine V920 (BPSC1001) | Open label, single center, dose escalation | $3 \times 10^{5} \text{pfu/mL (n = 10)}, 3 \times 10^{7} \text{pfu/mL (n = 10)}$ | Healthy eligible subjects between the ages of 18 and 55 years                      | Completed                         |
| Protocol V920-007-04 (Gabon) | 1     | Gabon   | A Phase 1, Randomized, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (V920) Ebola Virus Vaccine Candidate in Healthy Adult and Children Volunteers in Lambaréné, Gabon | Open label, dose escalation study | $3 \times 10^{5} \text{pfu/mL (n = 21)}, 3 \times 10^{7} \text{pfu/mL (n = 19)}$, placebo (n = 20) | Healthy eligible adults between the ages of 18 and 50 (later included a cohort of children 6 to 12 and adolescents 13 to 17 years of age) | Completed                         |
| Protocol V920-008-03 (Kenya) | 1     | Kenya   | A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (V920) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Kilifi, Kenya | Open label, dose escalation study | $3 \times 10^{5} \text{pfu/mL (n = 20)}$, placebo (n = 20) | Healthy eligible adult health workers ages 18–55 years                          | Completed                         |
| Protocol V920-009-05 | 2     | Liberia | Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) A Randomized Trial to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa | Randomized, double-blind, placebo-controlled study | $2 \times 10^{7} \text{pfu/mL (n = 500)}$, placebo (n = 500) | Subjects ≥18 years                                                                | Completed                         |
| Protocol V920-010-04 | 3     | Guinea  | A Randomized Trial to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa | Randomized ring vaccination | $2 \times 10^{7} \text{pfu/mL (n = 5837)}$, including 194 children 6–17 years of age | Subjects ≥18 years who live in the defined vaccination ring Expanded to include children 6–17 years of age in Protocol Amendment 4 | Completed                         |

(continued on next page)
| Study ID          | Phase | Country               | Study title                                                                 | Study design                                         | Dosing regimen (V920, IM)                                      | Study population                                           | Status of trial subject exposure¹                      |
|------------------|-------|-----------------------|-----------------------------------------------------------------------------|------------------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------|
| Protocol V920-011-05 | 2/3   | Sierra Leone          | Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE)            | Randomized, open label                               | $2 \times 10^7$ pfu/mL                                          | Subjects 18 years or older who are at high risk of exposure to EVD | Completed                                               |
| Protocol V920-012-02 | 3     | USA, Canada, Spain    | A Phase 3, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lots and a High Dose Lot of V920 Ebola Vaccine in Healthy Adults | Randomized, double-blind, placebo-controlled        | $2 \times 10^7$ consistency lot A (n = 266), $2 \times 10^7$ consistency lot B (n = 265), $2 \times 10^7$ consistency lot C (n = 266), $1 \times 10^8$ pfu/mL (n = 264), placebo (n = 133) | Healthy eligible subjects between the ages of 18 and 65 years | Completed                                               |
| Protocol V920-013-03 | 2     | USA, Canada           | A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (V920) for Pre-Exposure Prophylaxis (PREP) in Individuals at Potential Occupational Risk for Ebola Virus Exposure | Individuals at potential occupational risk, Randomized, Open label, booster or no booster at 18 months | Planned $2 \times 10^7$ pfu/mL (n ~ 800)                          | Subjects with potential occupational risk who are 18 years and older | Ongoing                                                  |
| Protocol V920-015-03 | 2     | Burkina Faso, Senegal | A Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of 1 or 2 doses of the V920 Ebola Virus Vaccine Candidate in HIV-Infected Adults and Adolescents | Randomized, double-blind, placebo-controlled, one or two doses of V920 | Planned $2 \times 10^7$ pfu/mL (n ~ 200), placebo (n ~ 50)       | HIV infected adults and adolescents                      | Ongoing                                                  |
| Protocol V920-016-03 | 2     | Guinea, Liberia       | Partnership for Research on Ebola Vaccination (PREVAC)                      | Randomized, double-blind, placebo-controlled trial of three vaccine strategies (Ad26.ZEBOV/ MVA-BN-Filo vaccine-Janssen, V920 with or without boost at 56 days) | Planned $2 \times 10^7$ pfu/mL (n ~ 1650) Placebo (n ~ 550) | Subjects (adults and children), aged at least 1 year of age | Ongoing (first subject enrolled in version 3.0 that includes dosing with V920 on 24-Jul-2017) |                                                         |
| Protocol V920-018-02 | 3     | Guinea                | A Randomized Trial to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa | Front Line Workers, open label                       | $2 \times 10^7$ pfu/mL                                          | All eligible frontline workers                             | Completed                                               |

Note: V920-014 is a placeholder for a potential pediatric clinical trial that is indefinitely on hold. V920-017 is an expanded access trial to be used in additional Ebola outbreaks in Africa.

¹ All studies administered a single dose of V920, except for the V920-002 trial in which 2 doses were administered; dose levels for V920 are nominal.
² Status of Trial subject exposure is current as of 01-Aug-2017.
³ Long-term follow-up is continuing for a subset of study participants.
### Table 2
Standardized template.

| Risk/benefit assessment for vaccine vectors |
|---------------------------------------------|
| **1. Basic Information** | Information |
| **1.1. Author(s)** | Thomas P. Monath M.D., Patricia E. Fast M.D., Ph.D., Kayvon Modjarrad, M.D., Ph.D., David Clarke, Ph.D., Brian K. Martin Ph.D., Joan Fusco Ph.D., R. Nichols M.S., D. Gray Heppner M.D., Jakub K Simon, M.D., M.S., Sheri Dubey, M.S., Sean P. Troth D.V.M, Ph.D., Beth-Ann Coller, Ph.D. |
| **1.2. Date completed/updated** | April 2018 |
| **2. Vaccine Vector information** | Information |
| **2.1. Name of Vaccine Vector** | rVSVAG-ZEBOV-GP (also designated V920). Recombinant Vesicular Stomatitis Virus Pseudo-typed with Ebola Zaire Glycoprotein |
| **2.2. Class/subtype** | Live, attenuated replication competent viral vector |
| **2.3. Proposed route of administration** | Intramuscular (IM) |

| **3. Characteristics of wild type agent** | Information | Comments/Concerns | Reference(s) |
|---------------------------------------------|-------------|------------------|--------------|
| **3.1. Please list any disease(s) caused by wild type, the strength of evidence, severity, and duration of disease for the following categories:** | | | |
| • In healthy people | Infection of humans with wild type VSV (wtVSV) New Jersey and Indiana serotypes can cause an influenza-like disease (usually without vesicle formation), incubation period 48 hrs, resolving in 3–5 days without complications. Mucosal ulceration and lymphadenopathy are reported. Rare cases are severe enough to warrant hospitalization Two published human cases of encephalitis caused by VSV have been reported, but are a rare complication of infection | Occupational exposure to wt or lab-adapted VSV strains (in veterinarians, farmers in livestock operations, laboratory workers) The reporting rate of naturally acquired overt disease with wtVSV in humans is very low, but in areas of Central and South America, infection appears to be common, with up to 94% of some populations being sero-positive. Surveys of individuals in close contact with VSV-infected livestock have shown high rates of seroconversion. Most infections may be asymptomatic or escape medical attention VSV sensu stricto is not present in Africa or in Europe Closely-related vesiculoviruses cause sporadic or epidemic encephalitis (Piry, Chandipura viruses in South America and India, respectively) | [50–59,65] |
| • In immunocompromised | Not known in humans | Immunosuppression with steroids did not potentiate wtVSV disease in experimentally infected swine Defects in innate immunity may underlie disease expression. VSV is exquisitely sensitive to IFN-α/β. Studies in mice lacking IFN receptors indicated that IFN response controls VSV replication | [60–62] |
| • In neonates, infants, children | Disease potential in children seems to be the same as that for adults | 7–18% of children 0–5 years of age reported to be seropositive in areas surveyed in South and Central America | [57,63] |
| • During pregnancy and in the unborn | There is no evidence that wtVSV can cause abortions in livestock following natural infection. However, in ferrets experimentally infected with wtVSV-I during the second half of pregnancy transplacental infection, fetal resorption, abortion or neonatal death were observed | The virus is biologically transmitted by biting insects such as sand-flies, black-flies and mosquitoes. Mechanical transmission by fomites, by non-biting flies and by animal-to-animal or animal-to-human transmission may occur through direct contact with vesicular lesions VSV must be differentiated from foot and mouth disease (FMDV) which has much more serious public health implications. Since FMDV does not affect horses, vesicular lesions in horses is a helpful differential diagnosis In experimentally infected ferrets, transplacental infection results in fetal resorption, stillbirth and neonatal death | [51,60,64,65] |
| • Are there any other susceptible human populations | Unknown | | |
| • Animals | Wild-type VSV-NJ and Indiana cause disease in livestock, typified by vesicular lesions around the mouth, nose, teats and coronary bands of the hooves. The disease in livestock is not lethal, and the lesions usually resolve in 10–11 days without complication. Affected animals may stop eating and lose weight and exhibit significant lameness Experimentally infected rodents, but not livestock, develop a detectable viremia following peripheral wtVSV-NJ and wtVSV-I infection | | |

(continued on next page)
3.2. Is there any known evidence of neurological or cardiac involvement of the wild type agent?

Two reported cases of neurologic disease (encephalitis) in humans. No known instances of cardiac involvement following natural infection with wtVSV

wtVSV-NJ and Indiana cause fatal encephalitis following intracerebral inoculation of livestock, non-human primates and rodents. wtVSV can also spread to the brain causing disease and in some cases death following intranasal (IN) and intravenous inoculation of monkeys

The related vesiculovirus, Chandipura virus is an important cause of epidemic encephalitis in children in India, with reported case fatality rates exceeding 50%

[53,65,66]

3.3. What is known about the types of human cells infected and the receptors used in humans and animals?

In livestock, wtVSV replication following scarification limited to skin (keratinocytes) and draining lymph nodes (MHC-II-positive cells)

Keratinocytes may also be a target cell in humans and are relatively resistant to type I interferons

wtVSV can infect a range of immortalized human cells in vitro. At one time phosphatidyl-serine was thought to be the major receptor for VSV; however, more recently this has been called into question. Recent work indicates that the receptor for VSV is the low-density lipid receptor (LDL-R), explaining the broad tropism of VSV viruses

In vivo, the range of susceptible cells may be more restricted; early research speculated that tissue associated monocytes may be one of the susceptible cell types in humans

Monocytes have been identified as a major class of infected cells following IM injection of rodents. Sub-populations of macrophages in the lymph nodes have specific features that make them more permissive for VSV replication. Following IN inoculation of mice the virus can replicate in nasal epithelia, and spread to the brain infecting neurons, astrocytes, glial and ependymal cells. The virus can also spread to and infect cells in the lungs after inoculation

The tropism of wtVSV differs from the recombinant viral vector vaccine which is pseudotyped with ZEBOV glycoprotein (discussed below)

[64,67–72]

3.4. Does the agent replicate in the nucleus?

No VSV replicates in the cell cytoplasm

[65]

3.5. What is the risk of integration into the human genome?

VSV is a non-segmented negative-strand RNA virus. Very low probability event (if not impossible)

The VSV RNA genome replicates in the cytoplasm, and is closely associated with the virus nucleocapsid protein. The VSV genome does not contain a gene for reverse transcriptase, and there is no DNA phase in the replication cycle that would allow integration

[64,68,73,74]

3.6. Does the agent establish a latent or persistent infection?

In nature, VSV causes persistent infection of arthropod vectors and is passed vertically through the arthropod egg to progeny flies

wtVSV can establish persistent infections in cell culture, due to the presence of specific mutations or through the activity of defective interfering (DI) particles. VSV activates many pathways of cell death and less virulent strains with inefficient induction of caspase-3-related apoptosis appear more likely to cause persistent infection

Persistent VSV infection has been established in mice and Syrian hamsters following intraperitoneal (IP) injection of virus in the presence of DI particles

See also Section 6.7

Persistent (latent) infection in naturally infected vertebrate hosts or humans has not been investigated

[18,60,72,73,75–77]

3.7. How does the wild type agent normally transmit?

In tropical America wtVSV is maintained in a cycle involving sandflies and rodents and possibly other small mammals. A variety of hematophagous insects transmit the virus to livestock and humans. Viremia is generally absent in livestock and their role as effective hosts for insect vectors remains unclear. Uninfected vectors may become infected when co-feeding on a host with infected flies. Infected livestock transmit to other animals by direct contact with vesicular lesions and fomites, including feeding troughs and cribbing boards. In addition to fomites, an important mode of spread appears to be mechanical transmission by horse and deer flies and muscoid flies and gnats feeding on secretions of infected livestock

The reservoir for VSV in nature is biting insects, as the virus can be passed vertically from adult to progeny flies through the egg and amplification by transmission between sandflies and viremic rodent hosts

[56,78–82]
3.8. What is known about the mechanisms of immunity to the wild type agent?

Immunity is acquired through a neutralizing antibody response to the virus G protein, which is located on the viral envelope. CD8 T-cell responses may also contribute to VSV immunity, and have been mapped to the virus N protein in BALB/c mice; other T cell epitopes presumably are present in the remaining 4 major virus proteins. Non-neutralizing antibodies may play a role in clearance of infected cells or virus killing through a variety of Fc-mediated phagocytic and cytotoxic mechanisms.

3.9. Is there treatment required and readily available for the disease caused by the wild type agent?

Livestock are typically not treated with any therapeutic agent because the disease is self-limiting and usually requires no treatment. Secondary bacterial infection can delay healing of lesions and can be treated with antibiotics. The disease in humans is usually not severe enough to warrant any special treatment.

4. Characteristics of proposed vaccine vector

4.1. What is the basis of attenuation/inactivation?

Attenuation is based principally on a reduction of viral replication and virulence due to deletion of the VSV G gene and replacement with the ebolavirus GP gene. The switch in envelope glycoprotein from VSV G protein to ZEBOV GP may also result in a change in cell tropism. The rVSVΔG-ZEBOV-GP (and other recombinant VSV vectors pseudotyped with filovirus GPs) viruses failed to replicate in Jurkat cells which are susceptible to wtVSV but not ebolavirus. Interestingly, however, the rVSVΔG-ZEBOV-GP virus was found to infect keratinocytes in humans, a feature of wtVSV, indicating that even with a foreign envelope protein, the rVSVΔG-ZEBOV-GP virus shares some tropism with the wtVSV virus. The rVSVΔG-ZEBOV-GP vaccine virus is not pathogenic by the peripheral route of inoculation in mice, hamsters, guinea pigs, nonobese diabetic–severe combined immunodeficient (NOD-SCID) mice, and normal and immunocompromised (SHIV infected) non-human primates. Neurovirulence of the vaccine is markedly attenuated. Whereas wtVSV is highly neurovirulent for all animals when inoculated by the intracerebral route, the rVSVΔG-ZEBOV-GP vaccine virus is virulent only for newborn mice. No clinical signs or significant histopathological lesions were observed in non-human primates inoculated by the intrathalamic route, whereas wtVSV was highly neurovirulent.

4.2. What is the risk of reversion to virulence or recombination with wild type or other agents?

No risk of recombination to reconstitute wtVSV during manufacture. There is no gene for wt VSV G protein involved in production of the vaccine. VSV derived vectors like other rhabdoviruses are susceptible to mutation due to infidelity of the viral polymerase and to deletion, generating defective interfering (DI) particles. Unlike positive strand viruses, negative-strand RNA viruses like VSV very rarely, if ever, recombine. VSV replication occurs in the cytoplasm of infected cells and involves RNA genomic and antigenic forms. Recombination to reconstitute genomes with the G gene of VSV from a wild-type virus and production of replication competent virus are extremely unlikely. Inter-strand recombination events during persistent infections of cells with VSV genomes can result in rearrangements of internal sequences as a result of polymerase errors; such events result in DI particle generation and do not represent a risk of increased virulence.

No VSV species or other heterologous vesiculoviruses are known in continental Africa, with which interspecies recombination could occur leading to new viruses with pathogenic potential.
4.3. Is the vector genetically stable during multiple passages? Yes

4.4. What is known about the genetic stability during in vivo replication? See Section 4.2

4.5. Will a replication competent agent be formed? The rVSVAG-ZEBOV-GP vaccine is replication competent. Recombination to produce a replication competent heterologous virus is highly unlikely (see Section 4.2)

4.6. What is the potential for shedding and transmission? There is minimal shedding and risk of transmission. The rVSVAG-ZEBOV-GP vaccine is infectious/immunogenic by oral and IN routes in nonhuman primates when given at high doses. Contact transmission (including via blood, fomites, and by mucosal routes) of vaccine virus likely requires high concentrations of virus in blood, or shedding in saliva and urine, which are not observed in humans after IM inoculation with the attenuated vaccine. In an unpublished study in pigs, animals inoculated with the vaccine in the skin of the snout and by the oro-nasal route developed a mild VSV-like disease with vesicular lesions but did not transmit virus to contact controls.

4.7. Will the agent survive in the environment? Viral replication occurs only in living cells. Compared to other enveloped RNA viruses wtVSV and rVSVAG-ZEBOV-GP appear to be quite stable ex vivo, however, the risk of environmental contamination from vaccinated subjects is low (see Section 4.6)
4.8. Is there a non-human ‘reservoir’?

There is no known or likely ‘reservoir’ of the rVSV-G-ZEBOV-GP vaccine virus. In non-human primates, replicating rVSV-DG-ZEBOV-GP virus is cleared from blood and tissues within the first week after inoculation by the immune response, although RNA persisted longer (up to 112 days) there was no evidence for infectious virus. Similarly, RNA of recombinant VSV expressing ovalbumin persisted in lymphatic tissues for up to 4 months, but there was no evidence for persistence of replicating virus. In humans, viremia and shedding is largely restricted to the first 1–3 days after inoculation, and is rarely found at 7 or 14 days, and has not be reported beyond that point to date. In mice inoculated IN with a recombinant VSV virus expressing ovalbumin RNA persisted in lung, spleen and lymph nodes for 6 weeks. In a published study in pigs experimentally infected with rVSVAG-ZEBOV-GP, virus was present at the site of intradermal inoculation in the snout and in draining lymph node tissue on day 3 but was cleared by day 21. In another (unpublished) study in young pigs, inoculation with a high dose of wtVSV or vaccine virus (by intradermal injection in the snout and oronasal instillation) resulted in a VSV-like illness in both groups. However, the vaccine virus infection was characterized by delayed onset of lesions and lower antibody responses, and pigs did not transmit the vaccine virus to contacts, whereas the wtVSV caused higher fever, early disease expression, high level antibodies and transmission to contacts. Further studies of the susceptibility of livestock to the vaccine virus are planned where virus inocula will be representative of potential exposure matched to levels of viremia and shedding in human vaccinees. While wtVSV has a reservoir in insects, transmission of rVSVAG-ZEBOV-GP by blood-feeding arthropods is considered highly unlikely. rVSV-DG-ZEBOV-GP viremia in humans is generally below the threshold for infection of blood-feeding arthropods (i.e. <1000 plaque-forming units/mL). Moreover, the rVSV-DG-ZEBOV-GP vaccine virus does not replicate in mosquito, sandfly or culicoid cell cultures in vitro, nor in Culex, Aedes, or Anopheles mosquitoes inoculated by the intrathoracic route. Culex and Aedes mosquitoes fed on blood containing a vaccine virus at a titer several log10 plaque forming units (pfu) more concentrated than would be observed in vaccinated individuals failed to become infected. In contrast wtVSV replicated after intrathoracic inoculation or oral ingestion of virus. [26,34,80,82,87,92]

4.9. Is there any evidence for or against safety during pregnancy?

There is currently limited evidence related to the safety of rVSVAG-ZEBOV-GP vaccine during pregnancy in humans. Pregnant women were excluded from clinical trials. Available data from women who became pregnant during the trials were reviewed at the World Health Organization Strategic Advisory Group of Experts meeting in October 2018. See the report cited for preliminary recommendations. Developmental and reproductive toxicology studies of the rVSVAG-ZEBOV-GP vaccine have been performed in a rat model in which viremic infection was induced during gestation. Administration of V920 (5.28×10^7 pfu/animal) showed no effect on mating, fertility, or fetal development following either single or multiple doses. [93,125]

4.10. Can the vector accommodate multigenic inserts or will several vectors be required for multigenic vaccines?

rVSVAG-ZEBOV-GP is not multigenic. However, rVSV is known to efficiently express multiple different proteins that are incorporated efficiently into the membrane protein of VSV, with or without co-incorporation with VSV G protein. If inserts have transmembrane regions, it is possible to accommodate and express multi-gene inserts. rVSV vectors with bivalent envelopes composed of influenza, Nipah and Andes viruses and Ebola GP proteins have been constructed. [19,94,95]

(continued on next page)
4.11. What is known about the effect of pre-existing immunity on 'take', safety or efficacy in animal models?

The rVSVAG-ZEBOV-GP vaccine is intended for single-dose primary immunization. Since the VSV G protein is deleted, the vaccine virus is not restricted by pre-existing antibodies against VSV. Anti-vector immunity based on antibodies or T cells to backbone VSV proteins (N, NS, M, L) could theoretically restrict replication and reduce immune response; however, available experimental data indicate that this is not likely to be a problem. Re-use of the vector for immunization with a different foreign transmembrane protein is therefore likely to be possible, and has been empirically demonstrated in non-human primates. Boosting (with the same vector) may be blunted by immunity to the incorporated foreign protein (i.e. ZEBOV GP) if given in the face of high levels of antibody, as observed for other live attenuated vaccines, but the interval for boosting (if required) has not been established.

VSV is not present in continental Africa or in Europe, nor are there known antigenically-related vesiculoviruses present in these regions that would provide anti-vector immunity. In the US and Latin America, antibodies to VSV are present. A study of rVSVAG-ZEBOV-GP vaccine immune responses in VSV seropositive versus seronegative humans did not show an impact of pre-existing VSV antibody on the anti-ZEBOV-GP IgG antibody response.

In a Phase 1 trial in which a second injection of rVSVAG-ZEBOV-GP was given 1 month after the first dose (at which time peak antibodies had developed), boosting of the IgG and neutralizing antibody levels was observed, although, as would be expected, the fold-increase was less than observed after the initial inoculation.

5. Manufacturing

5.1. Describe the source (e.g. isolation, synthesis)

rVSVAG-ZEBOV-GP is a live attenuated recombinant virus consisting of a single recombinant VSV-I with the gene for the ZEBOV GP replacing the gene for the VSV glycoprotein (G). This results in a replication competent pseudo-typed VSV with the ZEBOV GP comprising the envelope of the virion. See also Section 5.2.

5.2. Describe the provenance of the vector including passage history and exposure to animal products

The vaccine vector was derived by lipofectamine transfection of DNA plasmids containing genes for ZEBOV GP and VSV-I proteins (N, NS, M, L) into co-cultivated Vero (WHO-87) and HEK293 cell cultures with rescue of replication competent VSV-I pseudotyped with ZEBOV GP. The only exposure to animal products was fetal bovine serum (Australia-NZ origin) during the transfection step. Remaining passages were under serum and animal product-free conditions. Recombinant trypsin (TrypLE<sup>®</sup>) was used for cell expansion. Recombinant human serum albumin derived from rice was used as a stabilizer in final drug product.

5.3. Can the vector be produced in an acceptable cell substrate?

Yes. The vector grows to high titer (8–9 log<sub>10</sub> pfu/mL) in Vero cells. The latter are from a TSE-free stock (WHO-87) used for production of multiple other licensed vaccines, including live attenuated vaccines (e.g. oral polio, smallpox, dengue, Japanese encephalitis, and rotavirus).

5.4. Describe the production process

The MVS is used to infect Vero cells grown in roller bottles. The cell culture medium is harvested ~72 h after infection, and the virus harvest purified by depth filtration, Benzonase<sup>®</sup> + recombinant trypsin digestion (followed by addition of trypsin inhibitor), and ultracentrifugation. The purified drug substance is diluted to the desired potency with 10 mM Tris 2.5 mg/mL recombinant human serum albumin pH 7.2 to constitute the drug product. The latter is filled into 2 mL glass vials (extractable volume 1.0 mL) and frozen at ≤-60 °C.

5.5. What are some Purity/Potential contaminants?

The purification process has been well defined and documented. The level of host cell DNA is low (<10 ng/vaccine dose). Levels of residual host cell protein, Benzonase, and Trypsin are all low. Next generation sequencing is performed and shows the sequence of the Ebola GP is identical to the original plasmid used to construct the virus and no wrVSV genomes are detectable.

Reference(s)

[46,87,96]
| 6. Toxicology and potency (Pharmacology) | Information | Comments/Concerns | Reference(s) |
|----------------------------------------|-------------|------------------|--------------|
| **6.1. What is known about the replication, transmission and pathogenicity in animals?** | The rVSVAG-ZEBOV-GP vector causes no clinical illness in most animal species tested including mice, rats, guinea pigs, hamsters, ferrets, and rhesus and cynomolgus macaques and African green monkeys after peripheral inoculation. The only animal species in which overt clinical signs of infection with rVSVAG-ZEBOV-GP have been described is the pig. Young pigs inoculated in the apex of the snout and by the oro-nasal route with twice the full human dose (4 × 10^7 pfu) developed a mild clinical illness resembling wtVSV infection. See Section 4.8. After intracerebral inoculation, 1-day old mice develop lethal disease; but weaned animals are resistant. The virus is not pathogenic in weaned mice, guinea pigs and NHP after direct injection of the brain. No illness was observed in SCID-NOD mice or immunodeficient SHIV macaques after peripheral inoculation. | rVSVAG-ZEBOV-GP cGLP repeat dose toxicity studies in mice and NHP given moderate or high doses (up to 2.0 × 10^7 pfu/mouse and 1.0 × 10^8 pfu/NHP) of rVSVAG-ZEBOV-GP on days 1 and 14 have shown no toxicities at the clinical, clinical laboratory or histopathological levels. Replication of the attenuated rVSV vector in vivo is greatly restricted relative to wtVSV. | [18,37,87,90,97] |
| **6.2. For replicating vectors, has a comparative virulence, viral kinetic study been conducted in permissive/susceptible species? If not what species would be used for such a study? Is it feasible to conduct such a study?** | See Section 6.1. | All animal species are susceptible to lethal encephalitis when inoculated by the intracerebral route with wtVSV whereas only newborn mice are susceptible to rVSVAG-ZEBOV-GP. | [85,86,89,90,94–102] |
| **6.3. Does an animal model relevant to assess attenuation exist?** | Non-human primates are considered the gold-standard model for assessments of the virulence and attenuation of filovirus infections and vaccines. NHPs succumb to lethal hemorrhagic fever when inoculated by the intramuscular route with ZEBOV even at very low doses (i.e. >10 pfu), whereas rVSVAG-ZEBOV-GP causes no illness and no abnormalities in clinical laboratory tests when inoculated at doses up to 10^9 pfu. The Syrian hamster is highly susceptible to lethal illness after peripheral inoculation of both wtVSV and of ZEBOV (mouse-adapted strain), but not rVSVAG-ZEBOV-GP. | | |
| **6.4. Does an animal model for safety including immunocompromised animals exist?** | No illness was observed in SCID-NOD mice or immunodeficient SHIV macaques after peripheral inoculation of rVSVAG-ZEBOV-GP vaccine. The vaccine was fully attenuated in SHIV infected NHP. | wtVSV does not cause abortion or congenital infection or persistent infection in naturally infected livestock. Virulent wtZEBOV is known to cause severe outcomes in pregnant women but not congenital abnormalities. The virus may persist in semen and be transmitted by this route; however, these observations are of no known relevance to the highly attenuated recombinant rVSVAG-ZEBOV-GP vaccine. In a biodistribution study in NHP the vaccine virus did not persistently infect ovary or testicle. There is one report demonstrating ferrets are susceptible to congenital infection of wtVSV. No studies of recombinant VSV vectors have been performed in pregnant ferrets. | [89,90] |
| **6.5. Does an animal model for reproductive toxicity exist?** | Developmental and reproductive toxicity studies of rVSVAG-ZEBOV-GP have been conducted in a rat model in which viremia was induced during gestation and showed no toxicities. | | [87,93] |

(continued on next page)
6.6. Does an animal model for immunogenicity and efficacy exist?

Yes. Multiple published and unpublished studies in mouse, guinea pig and NHP models have demonstrated both immunogenicity of rVSVAG-ZEBOV-GP (and rVSV vectors expressing other foreign genes) and protection against lethal challenge with ZEBOV (and other viruses corresponding to the respective transgene). The rVSVAG-ZEBOV-GP vaccine is highly immunogenic across a very wide dose range (10^2–10^6 pfu) and protects virtually 100% of NHP against IM challenge with ~100 LD50 of the virulent challenge strain (7U) of ZEBOV. rVSVAG-ZEBOV-GP vaccinated NHP survive challenge but some animals have viremia and show mild clinical signs from which they survive. Since survival is the most frequent outcome of challenge it has been difficult to determine an immune correlate of protective immunity; this is an area of active study. In one published report, surviving mice, guinea pigs and NHP had significantly higher antibody levels pre-challenge or 7 days after challenge than non-survivors.

Complete and partial protection has been achieved with a single dose of rVSVAG-ZEBOV-GP given as early as three days prior to challenge of NHPs and before IgG antibodies were observed. The innate or adaptive mechanisms responsible for early protection in this model have not been fully defined, but very early protection may be due to the innate immune response, since protection against a heterologous filovirus (Marburg) was documented. The adaptive response (IgG and neutralizing antibodies) appears by 14 days after IM vaccination in humans and animals. Experimental studies have shown that antibodies (as opposed to CD8+ T cells) are critical to protection against future infection. Neutralizing IgM antibodies have also been suggested to play an important role in protection.

6.7. What is known about biodistribution?

A cGLP biodistribution study in cynomolgus macaques was performed using rVSVAG-ZEBOV-GP inoculated IM with 10^8 pfu. Animals were perfused to remove blood from tissues which were tested for RNA by qRT-PCR (VSV NP gene amplicon) and infectious virus by plaque assay. At 24 h after inoculation, vector RNA was detected in a variety of tissues indicating the pantropic nature of infection (adrenal gland, aorta, bone marrow, lung, injection site (muscle), liver, lymph node, spleen, pancreas, ovary or testicle, metacarpophalangeal joints, skin at injection site, and blood) in the rVSVAG-ZEBOV-GP-vaccinated animals, with highest levels in blood and lymphoid tissues (10^4–10^6 copies/mL). By day 28 only a few tissues (spleen, lymph node, ileum) were positive for RNA at a lower level (10^3–10^5 copies/mL), which persisted until end of study (day 112). Infectious virus was detected by plaque assay in bone marrow, injection site (muscle), femoral lymph node, spleen, and skin at injection site at 24h (10^3–10^5 pfu/g), with no evidence of viral replication at later time points measured (days 56, 84 and 112). Viral RNA after Day 7 was generally confined to tissues lacking potential for shedding in excretions or secretions and showed no evidence of distribution to the brain or spinal cord at any time point. The vaccine virus is present in blood of NHPs and humans given the nominal clinical dose of vaccine (2 x 10^7 pfu) IM during the first 3 days after vaccination, occasionally at day 7 and rarely on day 14, at which time most subjects have IgG antibodies. Virus-induced arthritis and/or skin or mucosal lesions, including vesicular lesions, petechial, and purpura have been noted in a small proportion (~5%) of vaccinees with onset generally in the 2nd week after inoculation (see details in Section 9.1). Vaccine virus has been identified in vesicle fluid as well as in keratinocytes at the site of a dermal lesion.

6.8. Have neurovirulence studies been conducted?

Yes. Neurovirulence testing has been performed on NHP by intra-thalamic injection; although not performed according to GLP, the study design was similar to that used for assessment of other live attenuated vaccines, including polio and yellow fever. rVSVAG-ZEBOV-GP was highly attenuated compared to wrVSV in this test. Neonatal miinoculated by the IC and IP routes surving the in vivo test for adventitious agents develop fatal illness; but weaned animals are resistant. For this reason, the in vivo test of V920 for adventitious agents in infant mice is not performed. In the biodistribution study in NHP (Section 6.7) there was no neuro-invasion despite high levels of virus in the bloodstream of 10^5 copies/mL.
6.9. What is the evidence that the vector will generate a beneficial immune response with ebolavirus or another disease in:

All species, including rodents, NHPs and humans develop robust ZEBOV-GP-specific antibody responses after inoculation of rSVAG-ZEBOV-GP vaccine across a wide range of doses. These immune responses are associated with nearly 100% protection against challenge (in experimental models) and with protection against ebolavirus disease in humans.

- **Rodent**
  Mice and Guinea pigs developed high titer durable IgG and neutralizing antibody responses after a single dose of rSV expressing ebolavirus GP and other antigens. T cell responses demonstrated in mice.

- **Nonhuman primates**
  Protection against uniformly lethal Ebola and Marburg infections has been repeatedly demonstrated in NHP immunized with rSVAG-based vaccines administered 4–6 weeks before IM challenge. Oral and intranasal routes of immunization have also been effective. Multiple studies have shown complete protection of NHP after a single IM inoculation of 1 × 10⁷ pfu rSVAG-ZEBOV-GP vaccinform a recent (unpublished) study using clinical grade vaccine 16/16 (100%) of animals immunized with 2 × 10⁷ pfu or 1 × 10⁶ pfu and 7/8 (88%) immunized with 3 × 10⁶ pfu as a single IM dose survived IM challenge with ~100 LD₅₀ of the highly lethal 7U Ebola Zaire strain. In a recently published NHP study, partial protection against EBOV challenge was observed 3 days after immunization, with full protection at 7 days after immunization. Post-exposure prophylaxis demonstrated in NHP if vaccine administered shortly (30m) after ZEBOV or Sudan ebolavirus challenge and up to 24 h after Marburg challenge.

- **Human**
  Most humans develop IgG and virus neutralizing antibodies after a single dose. Dose-ranging studies have shown high GP ELISA antibody titers across a wide dose range from 3 × 10³–10⁸ pfu given as a single IM inoculation. IgG antibody titers are statistically higher at doses ≥3 × 10⁷ pfu when compared to lower doses. IgG antibodies after the nominal clinical dose of ≥2 × 10⁷ pfu appear by day 14, peak at 28 days, and remain stable or decline slightly at 1 year. Seroconversion defined as ≥4 fold increase over baseline and a minimum value of 200 EU/mL occurs in ≥95% of subjects. Geometric mean endpoint IgG titers on day 28 are >50 fold higher than negative non-irradiated baseline and approximately 1000 EU/mL by a validated assay.
A cluster-randomized ring vaccination trial to evaluate efficacy was conducted during the 2014–2016 Ebola outbreak in Guinea, West Africa. The study identified a total of 117 rings around index cases of EVD and a total population of 11,841 including contacts and contacts of contacts (CCCs). Analysis of efficacy compared all vaccinated subjects in the immediate arm (2119 subjects in 51 rings) to all eligible subjects who consented on Day 0 in the delayed arm (1435 subjects in 46 rings). Ten cases of confirmed EVD (in 4 rings) were observed in eligible subjects in the delayed vaccination arm who consented on Day 0 while no cases of EVD occurred in the vaccinated subjects in the immediate arm >10 days after vaccination. The calculated vaccine efficacy in this analysis was 100% (95% CI: 63.5–100%, p = 0.0471).

6.10. Have challenge or efficacy studies been conducted with:
- HIV
  - Yes. rVSV-HIV vaccine candidates showed protection in macaques
  
- Other diseases
  - Yes. In various animal models, including rodents, rabbits, ferrets, and NHPs, rVSV vectored vaccines were immunogenic and protected against challenge with Zaire ebolavirus, Bundibugyo ebolavirus, Marburg, Lassa, influenza, chikungunya, SARS coronavirus, RSV, papillomavirus, Nipah and Lassa viruses

7. Previous Human Use

| 7.1. Has the vector already been used for targeting the disease of vector origin? | No |
| 7.2. What is known about the replication, transmission and pathogenicity of the vector in: | Yes |
| Healthy people? | rVSVAG-ZEBOV-GP has been administered to more than 18,000 healthy participants including approximately 235 children 6–17 years in thirteen Phase 1–3 clinical trials. rVSVAG-ZEBOV-GP was generally well tolerated. Injection site reactions following vaccination are very common and generally mild. Common systemic adverse events (AEs) include fever, headache, myalgia, arthralgia, and fatigue. Joint and skin adverse events have been described in <5% of subjects in most clinical trials. AEs are mostly mild to moderate in severity and of short duration with the exception of joint events that may last weeks to months and in care cases have been reported to persist for up to 2 years. Preliminary analyses suggest a slightly increased risk of developing joint events for women and subjects with a medical history of joint issues. Transient decreases in white blood cells have also been observed, but no increased risk of infection has been reported. rVSVAG-ZEBOV-GP viremia (based upon RNA detection) has been detected in almost all subjects in the first 3 days following vaccination in the studies in which this has been assessed; but appears to be less common after Day 3 postvaccination. Shedding of rVSVAG-ZEBOV-GP (based upon RNA detection) has rarely been observed in saliva, urine, and skin vesicles from adult vaccinees but has been observed more frequently among adolescents and children |
| Immunocompromised? | Unknown |
| | rVSVAG-ZEBOV-GP has been tested in a small number of HIV+ individuals in the Phase 2/3 program. Testing in additional HIV+ subjects is ongoing. |
**Neonates, infants, children?**

Unknown

Preliminary data from approximately 235 children 6–17 years of age who have received a nominal dose of $2 \times 10^7$ pfu rVSVAG-ZEBOV-GP vaccine suggests a similar safety profile to that seen in adult subjects. Trials of rVSVAG-ZEBOV-GP in larger numbers of adolescents and children down to 1 year of age are in progress.

**Elderly**

Unknown

The age cut-off for inclusion in Phase I–III trials has varied with the majority of trials limiting the maximum age to 65 years of age or less; the total number of elderly subjects is therefore limited. The ring vaccination trial (Guinea) included elderly subjects up to 100 years of age. The safety profile of V920 was generally consistent across age groups. For studies where immunogenicity was evaluated immune responses were consistent across age groups (no data for subjects >65 years of age).

**Pregnancy and in the unborn?**

Unknown

Pregnant women were excluded from the clinical trials. Available data from women who became pregnant during the trials were reviewed at the World Health Organization Strategic Advisory Group of Experts meeting in October 2018. See the report for preliminary recommendations.

**Gene therapy experiments?**

Unknown

Any other susceptible populations?

Unknown

**7.3. Is there any previous human experience with a similar vector including in HIV+ (safety and immunogenicity records)?**

Yes. rVSV with residual G protein expressing HIV-1 gag

Sixty healthy, HIV-1-uninfected adults received rVSV HIV-1 gag vaccine at 5 dose levels ($4.6 \times 10^7$ to $3.4 \times 10^7$ pfu or placebo with an acceptable safety profile of mild/moderate systemic reactogenicity. T cell responses to gag protein were seen in 63%.

**7.4. Is there any previous human experience with present vector including in HIV+ (safety and immunogenicity records)?**

Unknown

Preliminary data from approximately 20 HIV positive subjects that have received $2 \times 10^7$ pfu rVSVAG-ZEBOV-GP vaccine demonstrate similar safety results as seen in healthy adult subjects. Trials of rVSVAG-ZEBOV-GP are underway in HIV+ subjects with varying CD4+ counts >200/mm$^3$

**7.5. What is known about the effect of pre-existing immunity on ‘take’, safety or efficacy in any human studies with this or different insert?**

Yes. See Section 4.11. Deletion of VSV G protein eliminates anti-vector immunity mediated by neutralizing antibodies to VSV

See Section 4.11. Phase 1 data demonstrate that immune response to ZEBOV-GP is boosted by a second dose of rVSVAG-ZEBOV-GP

The rVSV vector has not yet been tested in human clinical trials for diseases other than HIV and ZEBOV. The direct public health considerations will remain the same as for the rVSV Ebola vaccine. It is unlikely that use of one rVSV vaccine will compromise future use of a similar rVSV vaccine expressing a different transmembrane protein, particularly for vectors that do not contain residual VSV G protein, as shown in a study of sequential immunization of NHPs with rVSV-Lassa and rVSV-ZEBOV.

**8. Overall Risk Assessment**

| Describe the toxicities | Please rate the risk as one of the following: none, minimal, low, moderate, high, or unknown | Comments | Reference(s) |
|-------------------------|------------------------------------------------------------------------------------------|----------|--------------|
| Hypersensitivity        | Minimal.                                                                                 |          | [97,125]     |

There have been two serious adverse event reports of anaphylaxis across the program with over 20,000 subjects vaccinated (>18,000 in Phase 1–3 trials and >20,000 in these trials plus expanded access protocols. One appears to have been associated with administration of amoxicillin for a different indication. The second case was a subject who developed generalized pruritus, urticaria, and oedema of the face and lips about 12 h after vaccination. The subject presented the following day, was treated with steroids, and improved without hospitalization.

(continued on next page)
Preliminary data from well controlled HIV+ individuals vaccinated in Liberia in the context of 2014 outbreak suggest that the safety profile was similar to HIV- subjects. An additional trial in a larger number of HIV+ individuals is ongoing.

No toxicities seen in immunocompromised SHIV infected macaques.

Preliminary data demonstrate similar safety in children older than 6 years of age compared to adults, however to date far fewer children have been vaccinated. A multicenter study in a large number of children and infants is in progress.

The age cut-off for inclusion in Phase I-III trials has varied with the majority of trials limiting the maximum age to 65 years of age or less: the total number of elderly subjects is therefore limited. The ring vaccination trial (Guinea) included elderly subjects up to 100 years of age. The safety profile of V920 was generally consistent across age groups. For studies where immunogenicity was evaluated immune responses were consistent across age groups (there are no data for subjects >65 years of age).

Pregnant women were excluded from the clinical trials. Available data from women who became pregnant during the trials were reviewed at the World Health Organization Strategic Advisory Group of Experts meeting in October 2018. In the STRIVE study in Sierra Leone (2015), there were a total of 104 pregnancies within 2 months of enrollment; of the women whose birth outcomes were known, there were no signals of untoward effects of vaccination. No abnormalities were observed in a GLP developmental and reproductive toxicity study in rats.

A limited number of persons >65 years of age were enrolled in the Guinea Ring vaccination trial. The safety profile in that population appears to be similar to that seen in subjects <65 years of age. Preliminary analyses suggest a slightly increased risk of developing joint events for women and subjects with a medical history of joint issues.

Deletion of VSV G protein markedly reduced neurotropism and neurovirulence of the recombinant vector in animal models. No toxicity after intrathalamic inoculation of NHP. No neuroinvasion in biodistribution study of NHP inoculated IM with $1 \times 10^8$ pfu (see Section 6.7).

Minimal and transient viremia levels in humans inoculated with up to $1 \times 10^8$ pfu minimizes potential for neuroinvasion across blood brain barrier.

Shedding in saliva appears to be dose related, but even at the highest doses tested shedding is infrequent and present at low levels (<1000 copies/mL, equates to <10 pfu/mL) in adults but may be higher in children and adolescents. Transmission risk appears to be very low.

Extensive testing of Vero cell bank for adventitious agents according to FDA and ICH guidelines with negative results. Minimal risk of TSE based on assessment of raw materials, cell line provenance, and passage history. Master Virus Seed assessed by PCR assays for mycoplasma and various human and animal viruses and by deep sequencing with negative results for adventitious viruses.

Minimal manufacturing process scaled to produce sufficient vaccine to meet anticipated epidemic preparedness and stockpiling requirements.

Multiple studies in mice, rats and NHPs, including neurovirulence, GLP repeat dose toxicity, GLP reproductive and developmental toxicity, and GLP biodistribution studies showed no toxicities.

>95% seroconversion of IgG and neutralizing antibodies and prevention of ebolavirus disease in humans in ring vaccination study. Protection against lethal challenge in multiple animal models.

Approximately 10–15% of subjects report injection site swelling and erythema, also

- Immunocompromised?
- Neonates, infants, children?
- Elderly
- Pregnancy and in the unborn?
- Other susceptible populations?

8.2. What is the risk of neurotoxicity/neuroinvasion or cardiac effects?

Meningoencephalitis, myocarditis

Minimal.

8.3. What is the potential for shedding and transmission in at risk groups?

Shedding in saliva and urine

Low.

8.4. What is the risk of adventitious agent (including TSE) contamination?

TSE or adventitious virus contamination

Minimal

8.5. Can the vector be manufactured at scale in an acceptable process?

Yes

Minimal

8.6. Can virulence, attenuation and toxicity be adequately assessed in preclinical models?

Yes

Minimal

8.7. Rate the evidence that a beneficial response will be obtained in humans.

High

High

9. Adverse Effect Assessment

Describe the adverse effects

Please rate the risk as one of the following: none, minimal, low, moderate, high, or unknown

Comments

Reference(s)

9.1. Describe the adverse effects observed

- Local reactions (mild to moderate in intensity)

Injection site reactions

High

Up to 82% of subjects report pain, majority are mild or moderate and self-limited.
Systemic reactions (mild to moderate in intensity)  
- Transient fever, chills, fatigue, headache, myalgia, arthralgia, lymphopenia  
  
Moderate  
Myalgia, fatigue, headache, fever, chills and lymphopenia in a large minority of subjects within the first several days after vaccination resolving within one week. The majority are mild to moderate in intensity.

This syndrome is associated with viremia and a signature of monocyte-activation cytokines/chemokines (MCP-1/CCL2, MIP1-β/CCL4, IL-6, TNF-α, IL-1Ra and IL-10). These effects are dose-dependent. One to two weeks following vaccination, <5% (in most trials, including a pivotal Phase 3 safety study with specific surveillance for joint and skin adverse events) of subjects also experience arthritis and/or rash (which in some cases may be vesicular or purpuric).

In some cases, viral RNA has been identified by immunohistochemistry and/or detection of vaccine virus RNA by RT-PCR in the joints or skin vesicles. In one Phase 1 study the incidence of oligoarthritis was as high as 22%. The reason for this difference is not well understood. In an open label safety study in Sierra Leone (STRIVE), 17% complained of joint pains in the interval 5–28 days after vaccination. Oligoarthritis, which typically has onset after day 5 is distinguished from arthralgia, which occurs earlier after vaccination and at a higher frequency but without objective physical signs (tenderness, swelling).

Several percent of subjects may report severe local reactions such as injection site pain post vaccination. Delayed onset transient arthritis may be considered severe in some subjects but is generally self-limited and resolves without persisting symptoms. In a small number of subjects ongoing symptoms have been reported out to 2 years postvaccination.

Severe local reactions  
- Transient injection site pain  
  
Minimal  
Several percent of subjects may report severe local reactions such as injection site pain.

Severe systemic reactions  
- Transient fever, chills, fatigue, headache, myalgia, arthralgia  
  
Minimal  
Several percent of subjects may report severe systemic reactions such as fever, headache, or arthralgia post vaccination.

10. Administration Assessment  

| Information | Comments/Concerns | Reference(s) |
|-------------|-------------------|--------------|
| **10.1.** What is the average Tissue Culture Infections Dose per millimeter (TCID/ml)? | Target dose $2.0 \times 10^7$ plaque forming units/mL as measured in validated potency assay | The target dose and associated release specifications are based on the minimal dose demonstrated to be efficacious and the maximum dose demonstrated to be safe in clinical trials. The final target potency value and associated specifications are derived from testing in a validated potency assay and differ from the nominal doses reported in the literature for the clinical trials (e.g. nominal dose of $2 \times 10^7$ pfu) which were derived from a non-validated assay. | [28,45,46,87,121,123] |
| **10.2.** What is the highest TCID/ml that can be used before cell toxicity? | Maximum *in vivo* toxicity is unknown | Humans have received a nominal dose of up to $1.0 \times 10^8$ pfu (measured in the non-validated assay) and the vaccine is generally well tolerated. Local and systemic adverse events are dose dependent, but vaccine associated arthritis appears to be dose-independent. Toxicity has not been observed in macaques up to a dose of $10^8$ pfu (measured in non-validated assay) | [28,45–47,121–123] |
| **10.3.** Are different demographics affected differently? | Preliminary analyses suggest that the incidence of arthritis may be 2–3 fold higher in female subjects and subjects with a medical history of joint problems | | [28,120] |

**References**

19
x. Key aspects of the Phase 1–3 clinical trials, which have engaged >18,000 participants are detailed in the template. Overall, when administered at the selected nominal dose of 2 × 10^7 pfu, rVSVAG-ZEBOV-GP vaccine has proven to be safe and well tolerated. During the first few days after vaccination, many vaccinees experience an acute-phase reaction with fever, headache, myalgia, and arthralgia of short duration; this period is associated with a low-level viremia, activation of anti-viral genes, and increased levels of chemokines and cytokines [28,39,125]. Oligoarthritis and rash appearing in the second week, occur in a minority of subjects, and are typically mild-moderate in severity and self-limited. Vesicular mucosal lesions are infrequent. The arthritis and skin events appear to reflect direct viral injury and inflammation and do not have an immunopathological basis [28,48]. As with any new vaccine, very rare adverse events may not be detected until accumulation of a large safety data base (1–3 million persons immunized).

y. The clinical trials have shown the vaccine to be highly immunogenic across a broad dose range of 3 × 10^2–1 × 10^8 pfu, with >95% of subjects developing IgG binding antibodies (ELISA using recombinant GP antigen) and neutralizing antibodies (using several different methods, but predominantly plaque reduction method with pseudotyped virus, e.g. rVSVAG-ZEBOV-GP) (Tables 1 and 2) [28,46–48]. Lower levels of neutralizing antibody to wild-type Ebola have been observed [28] possibly due to competition with sGP. IgG and neutralizing antibodies appear between days 7–14, peak on day 28, and plateau thereafter for at least 24 months.

z. All studies in humans (and most in NHP) have used the IM route of administration, and there has been no comparison to subcutaneous (SC) delivery. This is simply a reflection of the rapid pace of development of the vaccine.

aa. Efficacy of rVSVAG-ZEBOV-GP vaccine was demonstrated in a large ring vaccination trial in Guinea in which contacts of an Ebola case and contacts of contacts were randomized to receive a single injection of 2 × 10^7 pfu rVSVAG-ZEBOV-GP vaccine immediately or after a 21-day delay. [49,50] Analysis of efficacy in the randomized rings compared all vaccinated subjects in the immediate arm (2119 subjects in 51 rings) to all eligible subjects who consented on Day 0 in the delayed arm (1435 subjects in 46 rings). Ten cases of confirmed EVD (in 4 rings) were observed in eligible subjects in the delayed vaccination arm who consented on Day 0 while no cases of EVD occurred in the vaccinated subjects in the immediate arm >10 days after vaccination. The calculated vaccine efficacy in this analysis was 100% (95% CI: 63.5–100%, p = 0.0471). This remarkable trial was conducted while no cases of EVD occurred in the vaccinated subjects in the immediate arm (2119 subjects in 51 rings) who consented on Day 0. The calculated vaccine efficacy was 100% (95% CI: 63.5–100%, p = 0.0471). This remarkable trial was conducted at the tail end of the West African epidemic and underpins the regulatory review towards licensure of the vaccine, as well as pre-approval use in controlling outbreaks of Ebola virus disease.

ab. A summary of all clinical trials employing rVSVAG-ZEBOV-GP is provided in Table 1.

2. Disclaimer

The findings, opinions, conclusions, and assertions contained in this consensus document are those of the individual members of the Working Group. They do not necessarily represent the official positions of any participant’s organization (e.g., government, university, or corporations) and should not be construed to represent any Agency determination or policy.
van den Broek MF et al. Immune defence in mice lacking type I and/or type II interferon receptors. Immuno Mol 1995;148:5–18.

Howerton EW, Stallnacht DE, Dorminy M, et al. Experimental vesicular stomatitis in小麦 with routes of inoculation and steroid treatment. J Vet Diagn Invest 1997;9:136–42.

Jones SM, Strober U, Fernando L. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007;196:1304–12.

Tesh RB, Johnson KM. Vesicular stomatitis. In: Hubbert WT, editor. Diseases of domestic animals. 2002;7:217–24.

Nagata JT, Tesh RB, Johnson KM. Vesicular stomatitis virus: a review. J Vet Med Sci 1999;61:239–60.

Wong G, Pillet S, et al. Immune parameters correlate with experimental vesicular stomatitis virus infection in mice. J Virol 1997;71:3814–23.

Wong G et al. Immunization with vesicular stomatitis virus vaccine induces a Th2-type immune response. J Virol 1995;69:1897–902.

O'Hara PJ, Nichol ST, Hordyski FM, Holland JJ. Vesicular stomatitis virus infection in horses. J Infect Dis 1999;180:22–7.

Tesh RB, Modi GB, et al. Natural infection of humans, animals, and nonhuman primates with vesicular stomatitis virus. Rev Med Virol 2010;20:344–54.

Mead DG, Lovett KR, Murphy MD, et al. Transmission of vesicular stomatitis virus from infected to noninfected black flies co-feeding on nonviremic deer mice. J Med Entomol 1972;9:63–61.

Fultz PN, Shadduck JA, Kang CY, Streilein JW. Vesicular stomatitis virus can induce apoptosis. Cell 1984;36:915–24.

Mead DG, Lovett KR, Murphy MD, et al. Transmission of vesicular stomatitis virus in the Syrian hamster model of lethal Ebola virus infection. J Infect Dis 2011;204(Suppl. 3):S11090–7.

Chattopadhyay A, Wang E, Seymann R, et al. A chimeric VesiculoAlphavirus is an effective alphavirus vaccine. J Virol 2013;87:395–402.

Marzi A, Feldmann F, Geisbert TW, et al. Vesicular Stomatitis virus-based vaccines against Lassa and Ebola Viruses. Emerg Infect Dis 2015;21:305–7.

Merck & Co., Inc., Kenilworth, NJ, USA, Investigators Brochure Version 4. 2017 # 16131.

Jones S, Feldmann H, Stroher U. Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers. US Patent 8,012,498 Sept 6, 2011.

van den Pol AN, Dalton KP, Rose JP. Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol 2002;76:1109–27.

Frank AH, Appleby A, Sebold HR. Experimental intracerebral infection of horses, cattle, and sheep with the virus of vesicular stomatitis. Am J Vet Res 1945;28–38.

Geisbert TW, Bausch DG, Feldmann H. Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 2010:20:344–57.

Doba K, Robertson SJ, van der Werf TS, et al. VesicoVacc protects macaques against infection with the current Ebola virus outbreak strain. Science 2015;349:739–42.

Wong G, Richards SJ, Hordyski FM, et al. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012;4:158ra146.

Wong G et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection to nonhuman primates. Vaccine 2013;31:2522–5.

C.E. Mire JB, Geisbert, K.N. Agans et al. Durability of a vesicular stomatitis virus-based Marburg virus vaccine in nonhuman primates PLAS One 9 4 e94593.

Geisbert TW, Bausch DG, Feldmann H. VesicoVacc protects macaques against Ebola and nonhuman primates. Nat Med 2005;11:1239–47.

Mead DG, Lovett KR, Murphy MD, et al. Transmission of vesicular stomatitis virus vectors protects against challenge with a lethal dose of Ebola virus. J Infect Dis. 2015;212(Suppl. 2):S443–51.

Rampsburg E, Rose NF, Marx PA, et al. High efficacy of both vaccines to prevent Ebola in Liberia. New Eng J Med 2015;377:1436–87.

Lai L, Davey R, Beck A, et al. Emergency postexposure vaccination with vesicular stomatitis virus vector-based Ebola vaccine after needlestick. JAMA 2015;313:1249–55.

Elsheikh M, Brown B, Mackinnon-Cameron D, et al. A phase 1 randomized, placebo-controlled clinical trial assessing the safety and immunogenicity of a recombinant vesicular stomatitis virus Ebola vaccine in healthy adults. Can Med Assoc J 2017;189:E819–27.

Halperin SA, Arribas JB, Rupp R, et al. Six-month safety data of Ebola Zaire vaccine (rSVSAG-ZEBOV-GP) in a Phase III double blind, placebo controlled randomized study in healthy adults. J Infect Dis 2017;215:1789–98.

Agnani S, Fernandes JF, Bache EB, et al. Safety and immunogenicity of rSVSAG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene, Cen-
Gabon: a phase I randomised trial. PLoS Med 2017;14(10):e1002402. https://doi.org/10.1371/journal.pmed.1002402.

[122] Fuchs JD, Frank I, Elizaga ML, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090). Open Forum Infect Dis 2015;2(1):ofv082.

[123] Huttner A, Combescure C, Grillet S, et al. Plasma signature of the safety of the VSV Ebola vaccine in Europe and Africa. A dose-dependent plasma signature of innate immune responses to the VSV-Ebola vaccine reflects its biological outcomes and safety in Europe and Africa. Science Trans Med 2017;9(385). pii: eaaj1701.

[124] Samai M, Seward JF, Goldstein ST, et al. The Sierra Leone trial to introduce a vaccine Against Ebola: An evaluation of rVSVAC-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak. J Infect Dis 2018;217(Suppl. 1):S6–S15.

[125] WHO. SAGE Report 18 October 2018. <http://www.who.int/immunization/policy/sage/summary_sageoct18_report.pdf?ua=1>. 